Clene’s (CLNN) Buy Rating Reaffirmed at HC Wainwright

Clene (NASDAQ:CLNN)‘s stock had its “buy” rating restated by HC Wainwright in a research note issued to investors on Monday, Benzinga reports.

Separately, Weiss Ratings upgraded Clene from a “sell (e+)” rating to a “sell (d-)” rating in a report on Friday, October 9th. Six investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Clene presently has an average rating of “Moderate Buy” and a consensus target price of $34.00.

Clene Stock Up 6.1%

Shares of Clene stock traded up $0.19 during mid-day trading on Monday, reaching $3.29. 57,385 shares of the stock traded hands, compared to its average volume of 220,704. The stock has a market capitalization of $42.74 million, a PE ratio of -0.94 and a beta of 0.91. The business has a 50-day moving average of $4.04 and a 200 day moving average of $5.33. Clene has a fifty-two week low of $3.02 and a fifty-two week high of $13.50.

Clene (NASDAQ:CLNN) last issued its quarterly earnings results on Friday, August 14th. The company reported ($1.08) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.37) by ($0.71). The firm had revenue of $0.09 million during the quarter, compared to analysts’ expectations of $0.06 million. On average, equities research analysts expect that Clene will post -1.70 EPS for the current fiscal year.

Clene Company Profile

Clene Inc (NASDAQ: CLNN) is a clinical-stage biopharmaceutical company developing nanotherapeutic medicines for neurodegenerative diseases. The company’s platform uses clean-surfaced nanocrystals designed to influence cellular energy production and support the health and function of nerve cells.

Clene’s lead product candidate is CNM-Au8, an orally administered suspension of gold nanocrystals. The company has studied CNM-Au8 in conditions including amyotrophic lateral sclerosis (ALS), multiple sclerosis and Parkinson’s disease, with research focused on potential neuroprotective and remyelinating effects.